Compare ECF & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | SENS |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 301.2M |
| IPO Year | N/A | 2014 |
| Metric | ECF | SENS |
|---|---|---|
| Price | $13.42 | $6.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 37.0K | ★ 902.1K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | $29.61 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $9.58 | $0.41 |
| 52 Week High | $13.85 | $8.75 |
| Indicator | ECF | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 62.01 |
| Support Level | $11.33 | $6.62 |
| Resistance Level | N/A | $7.45 |
| Average True Range (ATR) | 0.24 | 0.39 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 72.66 | 85.29 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.